Last reviewed · How we verify
Acenocoumarol VKA
Acenocoumarol inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by antagonizing vitamin K recycling, thereby reducing thrombin generation and preventing blood clot formation.
Acenocoumarol inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by antagonizing vitamin K recycling, thereby reducing thrombin generation and preventing blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) prevention and treatment, Mechanical heart valve thromboprophylaxis.
At a glance
| Generic name | Acenocoumarol VKA |
|---|---|
| Sponsor | Sanofi |
| Drug class | Vitamin K antagonist (VKA) |
| Target | Vitamin K epoxide reductase complex (VKORC1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Acenocoumarol is a vitamin K antagonist (VKA) that works by inhibiting the vitamin K epoxide reductase complex, which is essential for the carboxylation and activation of vitamin K-dependent coagulation factors. This leads to decreased synthesis of functional factors II, VII, IX, and X, resulting in prolonged prothrombin time and reduced thrombotic risk. It is used for anticoagulation in conditions requiring long-term thromboembolic prevention.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism (deep vein thrombosis and pulmonary embolism) prevention and treatment
- Mechanical heart valve thromboprophylaxis
- Post-myocardial infarction thromboprophylaxis
Common side effects
- Bleeding (major and minor)
- Bruising
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Skin necrosis
Key clinical trials
- Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus (PHASE3)
- Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
- Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over
- Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care
- Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)
- Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation (PHASE3)
- Clinical Outcomes From Patient Self-management of Antivitamin K Treatment
- Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acenocoumarol VKA CI brief — competitive landscape report
- Acenocoumarol VKA updates RSS · CI watch RSS
- Sanofi portfolio CI